至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Identification of microRNA signature in the progression of gestational trophoblastic disease.

Cell Death Dis. 2018; 
ZhaoJiu-Ru,ChengWei-Wei,WangYa-Xin,CaiMei,WuWei-Bin,ZhangHui-
Products/Services Used Details Operation
Gene Synthesis Two double-digoxigenin (DIG)-labeled oligonucleotide probes, complementary to mature miR371a-5p (Exon Biotechnology, Guangzhou, China) and miR-518a-3p (Genscript, Nanjing, China), respectively, were synthesized Get A Quote

摘要

Gestational trophoblastic disease (GTD) encompasses a range of trophoblast-derived disorders. The most common type of GTD is hydatidiform mole (HM). Some of HMs can further develop into malignant gestational trophoblastic neoplasia (GTN). Aberrant expression of microRNA (miRNA) is widely reported to be involved in the initiation and progression of cancers. MiRNA expression profile also has been proved to be the useful signature for diagnosis, staging, prognosis, and response to chemotherapy. Till now, the profile of miRNA in the progression of GTD has not been determined. In this study, a total of 34 GTN and 60 complete HMs (CHM) trophoblastic tissues were collected. By miRNA array screening and qRT-P... More

关键词